Category «Uncategorized»

TOZADENANT

Tozadenant RO-449351 SYN-115 Molecular Formula C19H26N4O4S Average mass 406.499 Da A2 (3); A2a-(3); RO4494351; RO4494351-000; RO4494351-002; SYN-115 Phase III clinical trials at Biotie Therapies for the treatment of Parkinson’s disease as an adjunctive therapy with levodopa 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl- 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-1,3-benzothiazol-2-yl]-4-methyl-1-piperidinecarboxamide 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide 4-Hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide CAS 870070-55-6 Originator Roche Developer Acorda Therapeutics Class Amides; Antiparkinsonians; Benzothiazoles; Carboxylic acids; Morpholines; Piperidines; Small molecules Mechanism …

Prexasertib , прексасертиб , بريكساسيرتيب , 普瑞色替 ,

Prexasertib Captisol® enabled prexasertib; CHK1 Inhibitor II; LY 2606368; LY2606368 MsOH H2O 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile 2-Pyrazinecarbonitrile, 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]- Name Prexasertib Lab Codes LY-2606368 Chemical Name 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile Chemical Structure Molecular Formula C18H19N7O2 UNII UNII:820NH671E6 Cas Registry Number 1234015-52-1 OTHER NAMES прексасертиб [Russian] [INN] بريكساسيرتيب [Arabic] [INN] 普瑞色替 [Chinese] [INN] Originator Array BioPharma Developer Eli Lilly, National Cancer Institute Mechanism Of Action Checkpoint kinase inhibitors, Chk-1 inhibitors …

RAPASTINEL рапастинел , راباستينيل , 雷帕替奈

RAPASTINEL Molecular Formula C18H31N5O6 Average mass 413.469 Da L-threonyl-L-prolyl-L-prolyl-L-threoninamide (2S)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide 117928-94-6 [RN] L-Threoninamide, L-threonyl-L-prolyl-L-prolyl- рапастинел [Russian] راباستينيل [Arabic] 雷帕替奈 [Chinese] (S)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide UNII-6A1X56B95E; 117928-94-6; 6A1X56B95E (S)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide [117928-94-6] GLYX-13 trifluoroacetate GLYX-13;GLYX13;GLYX 13;Thr-Pro-Pro-Thr-NH2 L-Threonyl-L-prolyl-L-prolyl-L-threoninamide trifluoroacetate MFCD20527320 Thr-Pro-Pro-Thr-NH2 trifluoroacetate TPPT-amide trifluoroacetate UNII:6A1X56B95E BV-102; GLYX13, GLYX-13, in phase 3 clinical trials Originator Northwestern University Developer Allergan; Naurex Class Amides; Antidepressants; Neuropsychotherapeutics; Oligopeptides; Small molecules Mechanism of Action NR2B N-Methyl-D-Aspartate receptor agonists Highest …

ICH Q11 Q and A Document

ICH Q11 Q and A Document The topic of starting materials has been a vexed topic for some period. Indeed concerns relating to lack of clarity and issues pertaining to practical implementation led the EMA in Sept 2014 to publish a reflection paper—Reflection on the requirements for selection and justification of starting materials for …

Selective reductive amination of aldehydes from nitro compounds catalyzed by molybdenum sulfide clusters

Selective reductive amination of aldehydes from nitro compounds catalyzed by molybdenum sulfide clusters Green Chem., 2017, Advance Article DOI: 10.1039/C7GC01603D, Communication Open Access This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. E. Pedrajas, I. Sorribes, K. Junge, M. Beller, R. Llusar A one-pot selective synthesis of secondary amines catalyzed by …

Solithromycin, солитромицин , سوليثروميسين , 索利霉素 ,

Solithromycin Molecular Formula C43H65FN6O10 Average mass 845.009 Da CEM-101;OP-1068 UNII:9U1ETH79CK (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-Aminophenyl)-1H-1,2,3-triazol-1-yl]butyl}-4-ethyl-7-fluoro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxotetradecahydro-2H-oxacyclotetradecino[4 ;,3-d][1,3]oxazol-10-yl 3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoside 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 1-[4-[4-(3-aminophenyl)-1H-1,2,3-triazol-1-yl]butyl]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideox ;y-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- 3,4,6-Tridésoxy-3-(diméthylamino)-β-D-xylo-hexopyranoside de (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminophényl)-1H-1,2,3-triazol-1-yl]butyl}-4-éthyl-7-fluoro-11-méthoxy-3a,7,9,11,13,15-hex améthyl-2,6,8,14-tétraoxotétradécahydro-2H-oxacyclotétradécino[4,3-d][1,3]oxazol-10-yle CAS 760981-83-7 [RN] Solithromycin (trade name Solithera) is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP)[1] and other infections.[2] Solithromycin exhibits excellent in vitro activity against a broad spectrum of Gram-positive respiratory tract pathogens,[3][4] including macrolide-resistant strains.[5] Solithromycin has activity against most common respiratory Gram-(+) and fastidious Gram-(-) …

Enasidenib, Энасидениб , إيناسيدينيب ,伊那尼布 ,

Enasidenib Molecular Formula C19H17F6N7O Average mass 473.375 2-Propanol, 2-methyl-1-[[4-[6-(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]- 2-Methyl-1-[[4-[6-(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]-2-propanol 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol AG-221 CC-90007 1446502-11-9[RN] enasidenib Enasidenib énasidénib enasidenibum UNII:3T1SS4E7AG Энасидениб[Russian] إيناسيدينيب[Arabic] 伊那尼布[Chinese] 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol 2-methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol Originator Agios Pharmaceuticals Developer Celgene Corporation Mechanism Of Action Isocitrate dehydrogenase 2 inhibitor Who Atc Codes L01 (Antineoplastic Agents) Ephmra Codes L1 (Antineoplastics) Indication Cancer Enasidenib mesylate [USAN] RN: 1650550-25-6 UNII: UF6PC17XAV …

FDA approves new targeted treatment Idhifa (enasidenib)for relapsed or refractory acute myeloid leukemia

FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia 08/01/2017 The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime …

Eravacycline

Eravacycline http://www.ama-assn.org/resources/doc/usan/eravacycline.pdf 1-Pyrrolidineacetamide, N-[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)- 4-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]- (4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [(pyrrolidin-1-ylacetyl)amino]-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide 1207283-85-9 CAS 1334714-66-7 dihydrochloride TP 434-046 1-Pyrrolidineacetamide, N-[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-4-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl] MOLECULAR FORMULA C27H31FN4O8 MOLECULAR WEIGHT 558.6 SPONSOR Tetraphase Pharmaceuticals, Inc. CODE DESIGNATION TP-434 CAS REGISTRY NUMBER 1207283-85-9 WHO NUMBER 9702 Eravacycline (TP-434) is a synthetic fluorocycline antibiotic in development by Tetraphase Pharmaceuticals. It is closely related to the glycylglycine antibiotic tigecycline and the tetracycline class of antibiotics. It …

Polymers from biomass: one pot two-step synthesis of furilydenepropanenitrile derivatives with MIL-100(Fe) catalyst

Polymers from biomass: one pot two-step synthesis of furilydenepropanenitrile derivatives with MIL-100(Fe) catalyst Catal. Sci. Technol., 2017, 7,3008-3016 DOI: 10.1039/C7CY00463J, Paper Anastasia Rapeyko, Karen S. Arias, Maria J. Climent, Avelino Corma, Sara Iborra Monomers from biomass have been prepared from HMF and methylene active compounds through a one pot process using MIL-100(Fe)/TEMPO/NaNO2 as the catalytic system. Polymers …